Neal Navani

Neal Navani is an expert in Oncology at University College London Hospitals NHS Foundation Trust (United Kingdom). As of October 2026, ScienceLeadR ranks Neal Navani in the top 1% of experts worldwide for Lung Neoplasms and Thoracic Neoplasms. Neal Navani has authored 265 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 3 of them ongoing. SLR score: 955 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Pulmonology - Medical Imaging - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 28, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026

Source: PubMed

University College London

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 265

Citations

Citations: 13 449 1st author: 31 Last author: 47 Unique author: 3

Main journals

Lung Cancer 52

Thorax 31

J Thorac Oncol 17

Am J Respir Crit Care Med 16

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Experience of participating in a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in stage III-N2 non-small cell lung cancer: PIONEER. PMID 42933815 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics	BMJ Open Respir Res	2026
Radiomics machine learning models for lung cancer early diagnosis in heterogenous multicentre chest CT data: LIBRA study results. PMID 42831983 — early diagnosis, lung, neoplasms, machine learning, lung neoplasms, diagnosis, learning	Eur Radiol Exp	2026
Curative-Intent Radiotherapy in the Era of Earlier Lung Cancer Diagnosis: Insights from the National Lung Cancer Audit. PMID 42696944 — radiotherapy, early diagnosis, lung, neoplasms, lung neoplasms, diagnosis	Clin Oncol (R Coll Radiol)	2026
The effect of cigar, cigarillo and pipe smoking on lung cancer risk and screening eligibility. PMID 42567897 — lung, smokers, neoplasms, lung neoplasms, smoking, pipe smoking, tobacco products	Br J Cancer	2026
Brief Report: Translating Selection Criteria for Lung Cancer Screening to an Indian Context-An Analysis From a Tertiary Health Centre. PMID 42433330 — lung, translating, smokers, neoplasms, lung neoplasms	JTO Clin Res Rep	2026

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Director: 2

By phase:

N/A 10

Phase 3 1

Phase 4 1

By status:

Recruiting 4

Unknown 4

Active not recruiting 2

Completed 2

By type:

Observational 8

Interventional 4

By Monocentric/Multicentric:

monocentric 4

multicentric2to4 3

multicentric5to9 4

multicentricup10 1

Main Topics

Respiratory Tract Diseases 9

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Randomized Controlled Trial Comparing Percutaneous CT Guided Biopsy and Shape Sensing Robotic Assisted Bronchoscopy NCT07761351 — cone-beam computed tomography, lung, neoplasms, bronchoscopy, biopsy, multiple pulmonary nodules, lung neoplasms, biopsy, needle, diagnosis, needles	Phase 4	Recruiting	2026
An Observational Study of Predictors and Outcomes of Lung Cancer in Never smokers in the UK NCT06575439 — lung, smokers, neoplasms, lung neoplasms	N/A	Recruiting	2024
Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study NCT05432739 — early diagnosis, lung, immunophenotyping, neoplasms, biomarkers, lung neoplasms, diagnosis	N/A	Recruiting	2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice